Peer Review History

Original SubmissionMay 13, 2024
Decision Letter - Simone Garzon, Editor

PONE-D-24-17196Risk factors for emergent delivery before 36 weeks among pregnant women with placenta accreta spectrum disorderPLOS ONE

Dear Dr. Petpichetchian,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Reviewers appreciated the manuscript. However, some concerns are present. The main point regards adopted inclusion and exclusion criteria. The exclusion of cases who underwent elective CS before 36 weeks removed a population that may have worse characteristics from the study. A description of these cases and a comparison with the included population may be helpful. Second, a better description of methods, particularly US evaluation, is needed. 

Please submit your revised manuscript by Jan 04 2025 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org . When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.
  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.
  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols . Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols .

We look forward to receiving your revised manuscript.

Kind regards,

Simone Garzon

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at 

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. We note that your Data Availability Statement is currently as follows: All relevant data are within the manuscript and its Supporting Information files.

Please confirm at this time whether or not your submission contains all raw data required to replicate the results of your study. Authors must share the “minimal data set” for their submission. PLOS defines the minimal data set to consist of the data required to replicate all study findings reported in the article, as well as related metadata and methods (https://journals.plos.org/plosone/s/data-availability#loc-minimal-data-set-definition).

For example, authors should submit the following data:

- The values behind the means, standard deviations and other measures reported;

- The values used to build graphs;

- The points extracted from images for analysis.

Authors do not need to submit their entire data set if only a portion of the data was used in the reported study.

If your submission does not contain these data, please either upload them as Supporting Information files or deposit them to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. For a list of recommended repositories, please see https://journals.plos.org/plosone/s/recommended-repositories.

If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially sensitive information, data are owned by a third-party organization, etc.) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent. If data are owned by a third party, please indicate how others may request data access.

3. When completing the data availability statement of the submission form, you indicated that you will make your data available on acceptance. We strongly recommend all authors decide on a data sharing plan before acceptance, as the process can be lengthy and hold up publication timelines. Please note that, though access restrictions are acceptable now, your entire data will need to be made freely accessible if your manuscript is accepted for publication. This policy applies to all data except where public deposition would breach compliance with the protocol approved by your research ethics board. If you are unable to adhere to our open data policy, please kindly revise your statement to explain your reasoning and we will seek the editor's input on an exemption. Please be assured that, once you have provided your new statement, the assessment of your exemption will not hold up the peer review process.

Additional Editor Comments:

Reviewers appreciated the manuscript. However, some concerns are present. The main point regards adopted inclusion and exclusion criteria. The exclusion of cases who underwent elective CS before 36 weeks removed a population that may have worse characteristics from the study. A description of these cases and a comparison with the included population may be helpful. Second, a better description of methods, particularly US evaluation, is needed.

• I would suggest a language revision to improve some typos and grammatical errors.

• The introduction is well-written and clearly supports the study rationale.

• Methods. I would suggest providing some examples of conditions unrelated to PAS.

• Methods. Why did the authors exclude women who underwent planned delivery between 34-36 weeks? May this group represent patients without unplanned cesarean section?

• How was the list of patients retrieved, and eligible patients identified? Was a register of PAS cases present?

• Lines 135-140 highlight the cut-off of 36 weeks as the limit considered appropriate for all pregnancies with PAS. This questions why some patients underwent planned CS between 34-36 weeks. Because these patients were excluded, more severe cases would have been removed and representativeness reduced. I would suggest discussing this limitation of the study.

• Which is the source of data presented in lines 144-146?

• Lines 133-135. I would suggest clarifying the results of this evaluation. How were cases classified, and based on which criteria?

• Multivariable NOT multivariate

• Results. Lines 154-156. I would suggest providing some details regarding patients who underwent CS between 34-36 weeks and comparing them with the study population.

• Lines 166-167. Did the authors observe differences in the concordance rate based on the type of placental pathology?

• Table 1. What do the authors mean by the Number of PUCs? Number of episodes?

• Table 2. The Placenta previa is missing.

• I would suggest providing the definition for all US parameters in text or supplementary material to allow the study to be reproduced.

• Comparing outcomes between those who delivered before and after 36 weeks, considering that before 36 weeks, we only have emergent vs. both emergent and elective CS after, may introduce some biases.

• Providing the reasons for emergent CS of included cases would help understand whether these cases were mandatory. Moreover, comparing cases of those who had undergone elective CS before 36 weeks would allow for a more complete view.

• Discussion. Supporting that provided results would help identify patients who may benefit from an early elective CS around 34 weeks and require all emergent CS after 34 weeks. What is the mean gestational age at emergent CS?

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Thank you for a well written and researched article. However, I have a few minor corrections for better clarity

a. Page 10, lines 81-82: Cancel ‘s recent committee opinion’ as it is a repetition

b. Page 10, line 93: Cancel ‘and’

c. Page 11, lines 106-108, please clarify; Not clear

“, where delivery timing must be planned at approximately 34 weeks of DA to extend the pregnancy beyond 36 weeks

Reviewer #2: his is an extremely interesting retrospective study on the timing of delivery in pregnant women with placental abnormalities. The text is written in proper English, the statistical analysis appears methodologically sound, and the data presented in the results are consistent with the discussion. Overall, the study highlights possible risk factors that increase the likelihood of emergent preterm delivery in the patient category under study. It would be valuable to validate these findings by conducting a prospective study, which could help reduce the risk of bias.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean? ). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy .

Reviewer #1: No

Reviewer #2: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/ . PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org . Please note that Supporting Information files do not need this step.

Revision 1

Additional Editor Comments:

1. I would suggest a language revision to improve some typos and grammatical errors.

A professional editing service has been used to ensure the grammatical accuracy and readability of the manuscript.

2. The introduction is well-written and clearly supports the study rationale.

Thank you for your kind comment.

3 Methods. I would suggest providing some examples of conditions unrelated to PAS.

Examples have been added to the Methods section on page 5, ‘such as maternal hypertensive disorders or fetal growth restriction’.

4. Methods. Why did the authors exclude women who underwent planned delivery between 34-36 weeks? May this group represent patients without unplanned cesarean section?

As our research question was to determine factors that would help select women who would benefit from pregnancy continuation beyond 36 weeks, we thought it would be best to exclude this group of women because it was impossible to retrospectively determine that if these women did not undergo elective delivery at 34-36 weeks, whether they would fall into the group that could continue beyond 36 weeks or would require emergent delivery before 36 weeks.

5. How was the list of patients retrieved, and eligible patients identified? Was a register of PAS cases present?

As our institution is the sole referral center for PAS in the region, we set up a registry for PAS cases in 2016. Cases of placenta previa and PAS have been prospectively collected since 2016. The list of women with diagnoses before that time was retrieved and also added to the registry from the hospital’s electronic database. The primary investigator for this study then manually selected cases from the registry.

6. Lines 135-140 highlight the cut-off of 36 weeks as the limit considered appropriate for all pregnancies with PAS. This questions why some patients underwent planned CS between 34-36 weeks. Because these patients were excluded, more severe cases would have been removed and representativeness reduced. I would suggest discussing this limitation of the study.

The data regarding this group of women has been added in the Result section, and additional discussion has been provided.

7. Which is the source of data presented in lines 144-146?

The data were from reference number 6 ‘Morlando M, Schwickert A, Stefanovic V, Gziri MM, Pateisky P, Chalubinski KM, et al. Maternal and neonatal outcomes in planned versus emergency cesarean delivery for placenta accreta spectrum: a multinational database study. Acta Obstet Gynecol Scand. 2021;100 Suppl 1: 41-49. doi: 10.1111/aogs.14120’

8. Lines 133-135. I would suggest clarifying the results of this evaluation. How were cases classified, and based on which criteria?

The diagnosis of PAS by USG was based on the descriptors proposed by the European Working Group on Abnormally Invasive Placenta. This clarification, along with the reference (no.19), has been added to the manuscript.

9. Multivariable NOT multivariate

Corrections have been made on pages 2 and 14

10. Results. Lines 154-156. I would suggest providing some details regarding patients who underwent CS between 34-36 weeks and comparing them with the study population.

Additional details about the group of patients are provided in the last paragraph of the Result section.

11. Lines 166-167. Did the authors observe differences in the concordance rate based on the type of placental pathology?

Yes, and the details were added into the text as follows.

A diagnosis of PAS was histologically confirmed in 150 patients (86.2%) and was more frequent in women with a prenatal suspicion of placenta percreta (26/26 women, 100%) than in those with placenta increta (77/84 women, 91.7%) or accreta (47/64 women, 73.4%).

12. Table 1. What do the authors mean by the Number of PUCs? Number of episodes?

Yes. For clarity, the term in the table has been changed to ‘episodes of PUCs.’

13. Table 2. The Placenta previa is missing.

Yes. That is because we included only cases with suspected PAS. Therefore, cases with a prenatal diagnosis of placenta previa alone were excluded.

14. I would suggest providing the definition for all US parameters in text or supplementary material to allow the study to be reproduced.

The ultrasound descriptors are in accordance with the reference that was mentioned earlier.

15. Comparing outcomes between those who delivered before and after 36 weeks, considering that before 36 weeks, we only have emergent vs. both emergent and elective CS after, may introduce some biases.

Additional details and discussion about the group that delivered electively at 34-36 weeks regarding the delivery outcomes have been provided.

16. Providing the reasons for emergent CS of included cases would help understand whether these cases were mandatory. Moreover, comparing cases of those who had undergone elective CS before 36 weeks would allow for a more complete view.

Reasons for emergent delivery have been added to the Results section (lines 175-178)

Additional details and discussion regarding the delivery outcomes have been provided about the group that delivered electively at 34-36 weeks.

17. Discussion. Supporting that provided results would help identify patients who may benefit from an early elective CS around 34 weeks and require all emergent CS after 34 weeks. What is the mean gestational age at emergent CS?

This information has been added to the Results as follows,

‘Emergent delivery before 36 weeks of GA was required in 45 (25.0%) women (mean GA at delivery 32+6 weeks), whereas pregnancy continued beyond 36 weeks of GA in 129 (75.0%) women (mean GA at delivery 37 weeks).’

Reviewer #1:

Thank you for a well written and researched article. However, I have a few minor corrections for better clarity

18. Page 10, lines 81-82: Cancel ‘s recent committee opinion’ as it is a repetition

Thank you. The correction has been made.

19. Page 10, line 93: Cancel ‘and’

Thank you. The correction has been made.

20. Page 11, lines 106-108, please clarify; Not clear

“, where delivery timing must be planned at approximately 34 weeks of DA to extend the pregnancy beyond 36 weeks

The text has been changed to ‘…where delivery timing must be planned at approximately 34 weeks GA, regarding whether to perform elective delivery before 36 weeks or extend the pregnancy beyond 36 weeks.’

Reviewer #2: his is an extremely interesting retrospective study on the timing of delivery in pregnant women with placental abnormalities. The text is written in proper English, the statistical analysis appears methodologically sound, and the data presented in the results are consistent with the discussion. Overall, the study highlights possible risk factors that increase the likelihood of emergent preterm delivery in the patient category under study. It would be valuable to validate these findings by conducting a prospective study, which could help reduce the risk of bias.

Thank you for your positive comments.

Decision Letter - Simone Garzon, Editor

Risk factors for emergent delivery before 36 weeks among pregnant women with placenta accreta spectrum disorder

PONE-D-24-17196R1

Dear Dr. Petpichetchian,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager®  and clicking the ‘Update My Information' link at the top of the page. If you have any questions relating to publication charges, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Simone Garzon

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

The manuscript and the reviewers’ comments were carefully evaluated. The Reviewers appreciated the manuscript and the improvements. Now it can be accepted. Compliments!

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #2: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #2: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #2: I believe that the author has made the necessary revisions to the manuscript in accordance with the feedback and recommendations provided by both the editor and the reviewers. I highly appreciate the effort put into addressing these points, and I find the revised version to be significantly improved and more aligned with the required standards.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean? ). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy .

Reviewer #2: No

**********

Formally Accepted
Acceptance Letter - Simone Garzon, Editor

PONE-D-24-17196R1

PLOS ONE

Dear Dr. Petpichetchian,

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now being handed over to our production team.

At this stage, our production department will prepare your paper for publication. This includes ensuring the following:

* All references, tables, and figures are properly cited

* All relevant supporting information is included in the manuscript submission,

* There are no issues that prevent the paper from being properly typeset

If revisions are needed, the production department will contact you directly to resolve them. If no revisions are needed, you will receive an email when the publication date has been set. At this time, we do not offer pre-publication proofs to authors during production of the accepted work. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few weeks to review your paper and let you know the next and final steps.

Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

If we can help with anything else, please email us at customercare@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Simone Garzon

Academic Editor

PLOS ONE

Open letter on the publication of peer review reports

PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.

We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.

Learn more at ASAPbio .